Genzyme touts Renagel data

Genzyme Corporation said its three-year study of 2,100 dialysis patients showed that its Renagel drugs is better than calcium-based phosphate binders at prolonging patients' lives. The drug was particularly effective in those patients treated with Renagel for two years or more, and in those 65 or older.

- read this release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.